Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

In patients with cytopenic myelofibrosis, treatment with the JAK2/IRAK1 inhibitor pacritinib was associated with anemia benefit in the phase 3 PERSIST-2 study. The impact of pacritinib on transfusion independence (TI) has not been previously described, nor has the mechanism by which pacritinib impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Stephen T., Mesa, Ruben A., Harrison, Claire N., Bose, Prithviraj, Gerds, Aaron T., Gupta, Vikas, Scott, Bart L., Kiladjian, Jean-Jacques, Lucchesi, Alessandro, Kong, Tim, Buckley, Sarah A., Tyavanagimatt, Shanthakumar, Harder, Bryan G., Roman-Torres, Karisse, Smith, Jennifer, Craig, Adam R., Mascarenhas, John, Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561048/
https://www.ncbi.nlm.nih.gov/pubmed/37552106
http://dx.doi.org/10.1182/bloodadvances.2023010151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561048/
https://www.ncbi.nlm.nih.gov/pubmed/37552106
http://dx.doi.org/10.1182/bloodadvances.2023010151

Ejemplares similares